Literature DB >> 28263557

Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy.

Philipp Ottis1, Craig M Crews1.   

Abstract

Until recently, the only ways to reduce specific protein signaling were to either knock down the target by RNAi or to interfere with the signaling by inhibiting an enzyme or receptor within the signal transduction cascade. Herein, we review an emerging class of small molecule pharmacological agents, called PROTACs, that present a novel approach to specifically target proteins and their respective signaling pathways. These heterobifunctional molecules utilize endogenous cellular quality control machinery by recruiting it to target proteins in order to induce their degradation.

Mesh:

Substances:

Year:  2017        PMID: 28263557     DOI: 10.1021/acschembio.6b01068

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  52 in total

Review 1.  Transcription Factor Inhibition: Lessons Learned and Emerging Targets.

Authors:  Andrew Chen; Angela N Koehler
Journal:  Trends Mol Med       Date:  2020-02-15       Impact factor: 11.951

2.  Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC).

Authors:  Caroline M Robb; Jacob I Contreras; Smit Kour; Margaret A Taylor; Mohammad Abid; Yogesh A Sonawane; Muhammad Zahid; Daryl J Murry; Amarnath Natarajan; Sandeep Rana
Journal:  Chem Commun (Camb)       Date:  2017-07-04       Impact factor: 6.222

Review 3.  Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities.

Authors:  Rachel J Harding; Yu-Feng Tong
Journal:  Acta Pharmacol Sin       Date:  2018-04-05       Impact factor: 6.150

4.  PROTAC Molecules for the Treatment of Autoimmune Disorders.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2019-02-15       Impact factor: 4.345

5.  Treatment of Prostate Cancers and Kennedy's Disease by PROTAC-Androgen Receptor Degradation.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2019-04-01       Impact factor: 4.345

6.  Treatment of Alzheimer's by PROTAC-Tau Protein Degradation.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2019-03-12       Impact factor: 4.345

Review 7.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

8.  Twenty years of bioinformatics research for protease-specific substrate and cleavage site prediction: a comprehensive revisit and benchmarking of existing methods.

Authors:  Fuyi Li; Yanan Wang; Chen Li; Tatiana T Marquez-Lago; André Leier; Neil D Rawlings; Gholamreza Haffari; Jerico Revote; Tatsuya Akutsu; Kuo-Chen Chou; Anthony W Purcell; Robert N Pike; Geoffrey I Webb; A Ian Smith; Trevor Lithgow; Roger J Daly; James C Whisstock; Jiangning Song
Journal:  Brief Bioinform       Date:  2019-11-27       Impact factor: 11.622

9.  Optical Control of Small Molecule-Induced Protein Degradation.

Authors:  Yuta Naro; Kristie Darrah; Alexander Deiters
Journal:  J Am Chem Soc       Date:  2020-01-23       Impact factor: 15.419

10.  Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.

Authors:  Ka Yang; Hao Wu; Zhongrui Zhang; Eric D Leisten; Xueqing Nie; Binkai Liu; Zhi Wen; Jing Zhang; Michael D Cunningham; Weiping Tang
Journal:  ACS Med Chem Lett       Date:  2020-03-18       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.